Results 121 to 130 of about 51,702 (211)

Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS. [PDF]

Mult Scler
Arnold DL, Kolind S, Assemlal HE, Bar-Or A, Inglese M, Kappos L, Parmar K, Sprenger T, Traboulsee A, Vavasour IM, Wolinsky JS, Bernasconi C, Bonati U, Magon S, Tackenberg B, Gaetano L.   +15 more
europepmc   +1 more source

Estimating individual treatment effect on disability progression in multiple sclerosis using deep learning. [PDF]

Nat Commun, 2022
Falet JR, Durso-Finley J, Nichyporuk B, Schroeter J, Bovis F, Sormani MP, Precup D, Arbel T, Arnold DL.   +8 more
europepmc   +1 more source

Communications [PDF]

, 2011
Marissen, Michael, Roberts, J. H.
core   +2 more sources

Late-onset severe neutropenia in patients with relapsing remitting multiple sclerosis treated with ocrelizumab: case report and literature review. [PDF]

Front Neurosci
Tauro C, Awada Z, Malhotra R, Harel A.
europepmc   +1 more source

Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal. [PDF]

Pharmacoecon Open, 2023
Martins P, Vandewalle B, Félix J, Capela CM, Cerqueira JJ, Salgado AV, Ferreira DG, Monteiro I.   +7 more
europepmc   +1 more source

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. [PDF]

Eur J Neurol, 2022
Butzkueven H, Spelman T, Horakova D, Hughes S, Solaro C, Izquierdo G, Kubala Havrdová E, Grand'Maison F, Prat A, Girard M, Hupperts R, Onofrj M, Lugaresi A, Taylor B, MSBase Study Group, Giovannoni G, Kappos L, Hauser SL, Montalban X, Craveiro L, Freitas R, Model F, Overell J, Muros-Le Rouzic E, Sauter A, Wang Q, Wormser D, Wolinsky JS.   +27 more
europepmc   +1 more source

Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials. [PDF]

Ther Adv Neurol Disord
Derfuss T, Bermel R, Lin CJ, Hauser SL, Kappos L, Vollmer T, Comi G, Giovannoni G, Hartung HP, Weber MS, Wang J, Jessop N, Chognot C, Craveiro L, Bar-Or A.   +14 more
europepmc   +1 more source

Optimizing premedications for multiple sclerosis patients treated with ocrelizumab: A randomized controlled trial. [PDF]

Mult Scler J Exp Transl Clin
Abbasi Kasbi N, Rezaei A, Montazeri R, Nikkhah Bahrami S, Rezaeimanesh N, Arab Bafrani M, Ghane Ezabadi S, Kohandel K, Khodaie F, Jahani S, Naser Moghadasi A, Azimi Saeen A, Navardi S, Heidari H, Ebadi Z, Sahraian MA.   +15 more
europepmc   +1 more source

Machine learning-based prediction of disease progression in primary progressive multiple sclerosis. [PDF]

Brain Commun
Gurevich M, Zilkha-Falb R, Sherman J, Usdin M, Raposo C, Craveiro L, Sonis P, Magalashvili D, Menascu S, Dolev M, Achiron A.   +10 more
europepmc   +1 more source

La Musique du Diable (1711): an obscure specimen of fantastic literature throws light on the elusive opera diva Marie-Louise Desmatins (fl. 1682–1708) [PDF]

, 2007
Chrissochoidis, I.
core